Alzeca Biosciences

Alzeca Biosciences is a private, early-stage diagnostics company targeting the massive and growing unmet need in Alzheimer's Disease detection. Its core innovation is the development of advanced contrast agents for MRI and CT scans, which could allow for the identification of disease pathology years before cognitive symptoms appear, at a lower cost and with greater global accessibility than current PET-based methods. The company is led by an experienced management team with deep expertise in diagnostic imaging and is supported by private investors and grants from organizations like the Cure Alzheimer's Fund and NIH.

Development of novel imaging contrast agents (for MRI and CT scanners) that target pathological hallmarks of neurodegenerative diseases to enable early diagnosis.

Alzeca competes with companies offering FDA-approved amyloid PET tracers (e.g., Eli Lilly's Amyvid, GE Healthcare's Vizamyl) and tau PET tracers, which are the current diagnostic gold standard but are expensive and have limited access. It also faces potential competition from blood-based biomarker tests in development. Alzeca's key differentiation is leveraging ubiquitous MRI/CT infrastructure for lower-cost, scalable screening.